Contributions of LabelLibby

Contributions by LabelLibby, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 999 edits includes activity predating the current log.

1. 08:52, 10 Jun 2026 (diff | hist) Talk:Multi-dose vial 1,581 +127 /* Preservative concentration table: are these current products or historical? */ reply
2. 11:26, 8 Jun 2026 (diff | hist) Talk:Multi-dose vial 948 +286 /* Preservative concentration table: are these current products or historical? */ new section
3. 10:15, 5 Jun 2026 (diff | hist) Talk:Regulatory status by jurisdiction 537 +167 /* Presentation test */ new section
4. 15:26, 2 Jun 2026 (diff | hist) Customs seizure 4,785 ±0 attribute the enforcement statement to the published policy
5. 10:15, 31 May 2026 (diff | hist) Talk:Timeline of incretin therapeutics 537 +106 /* Approval dates are jurisdictional */ new section
6. 15:07, 19 May 2026 (diff | hist) Glucagon-like peptide-1 12,294 ±0 clarify that the receptor is expressed outside the pancreas
7. 11:03, 11 Apr 2026 (diff | hist) Personal importation policy 4,121 ±0 m rm the claim that the position has changed; no source supports it
8. 13:45, 19 Mar 2026 (diff | hist) Talk:Active pharmaceutical ingredient 611 +165 /* Pharmaceutical grade is not a term */ reply
9. 09:45, 10 Mar 2026 (diff | hist) Talk:Prescribing information 400 +128 /* Warnings versus contraindications */ new section
10. 13:15, 27 Feb 2026 (diff | hist) Talk:Missed dose 611 +156 /* Not a substitute for labelling */ reply
11. 09:45, 20 Feb 2026 (diff | hist) Talk:Contraindications of incretin therapy 400 +137 /* Contraindication is a labelling concept */ new section
12. 11:02, 4 Feb 2026 (diff | hist) Talk:Beyond-use date 1,033 +294 /* RfC: are beyond-use date and expiration date being conflated across the wiki? */ reply
13. 00:44, 16 Jan 2026 (diff | hist) Research use only 7,990 ±0 state that research-use-only labelling is a commercial category, not an approval
14. 14:46, 14 Oct 2025 (diff | hist) ISO 9001 4,278 ±0 add category for drug regulation
15. 23:50, 20 Sep 2025 (diff | hist) Good manufacturing practice 5,123 ±0 name the regulator rather than writing "the authorities"
16. 09:26, 30 Aug 2025 (diff | hist) Talk:Temperature excursion 1,170 +229 /* In-use allowance table: which jurisdiction? */ reply
17. 14:19, 27 Aug 2025 (diff | hist) Talk:Temperature excursion 537 +267 /* In-use allowance table: which jurisdiction? */ new section
18. 10:58, 27 May 2025 (diff | hist) Customs seizure 3,644 ±0 add the patent-expiry statement, attributed and dated
19. 02:11, 17 Apr 2025 (diff | hist) Personal importation policy 3,251 +96 add category for drug regulation
20. 23:14, 13 Apr 2025 (diff | hist) Customs seizure 3,644 +497 m fix the anchor on an internal link
21. 16:40, 26 Mar 2025 (diff | hist) Glucose-dependent insulinotropic polypeptide 6,686 ±0 m move the trial material out of §Physiology into the compound articles
22. 07:39, 4 Dec 2024 (diff | hist) Personal importation policy 1,572 ±0 m add the effective date to the regulatory table
23. 02:17, 29 Nov 2024 (diff | hist) Active pharmaceutical ingredient 1,752 +609 add the customs-detention point with its source
24. 07:49, 1 Oct 2024 (diff | hist) Bachem Holding (Suzhou) 1,692 ±0 m rm the comparison with another supplier; there is no common basis for it
25. 05:43, 23 Sep 2024 (diff | hist) Research use only 3,527 +334 add category for drug regulation